S&P 500   3,298.46 (+1.60%)
DOW   27,173.96 (+1.34%)
QQQ   271.75 (+2.40%)
AAPL   112.48 (+3.94%)
MSFT   207.74 (+2.24%)
FB   255.04 (+2.21%)
GOOGL   1,441.99 (+1.34%)
AMZN   3,094.00 (+2.46%)
TSLA   407.87 (+5.18%)
NVDA   514.70 (+4.21%)
BABA   270.64 (+0.34%)
CGC   14.13 (-0.98%)
GE   6.11 (+0.83%)
MU   49.10 (-0.75%)
AMD   78.05 (+2.94%)
T   28.03 (-0.04%)
F   6.52 (-2.10%)
ACB   5.03 (-3.27%)
GILD   62.23 (-0.03%)
NFLX   481.88 (+1.86%)
DIS   124.00 (+1.23%)
BAC   23.49 (+0.64%)
BA   156.49 (+7.15%)
S&P 500   3,298.46 (+1.60%)
DOW   27,173.96 (+1.34%)
QQQ   271.75 (+2.40%)
AAPL   112.48 (+3.94%)
MSFT   207.74 (+2.24%)
FB   255.04 (+2.21%)
GOOGL   1,441.99 (+1.34%)
AMZN   3,094.00 (+2.46%)
TSLA   407.87 (+5.18%)
NVDA   514.70 (+4.21%)
BABA   270.64 (+0.34%)
CGC   14.13 (-0.98%)
GE   6.11 (+0.83%)
MU   49.10 (-0.75%)
AMD   78.05 (+2.94%)
T   28.03 (-0.04%)
F   6.52 (-2.10%)
ACB   5.03 (-3.27%)
GILD   62.23 (-0.03%)
NFLX   481.88 (+1.86%)
DIS   124.00 (+1.23%)
BAC   23.49 (+0.64%)
BA   156.49 (+7.15%)
S&P 500   3,298.46 (+1.60%)
DOW   27,173.96 (+1.34%)
QQQ   271.75 (+2.40%)
AAPL   112.48 (+3.94%)
MSFT   207.74 (+2.24%)
FB   255.04 (+2.21%)
GOOGL   1,441.99 (+1.34%)
AMZN   3,094.00 (+2.46%)
TSLA   407.87 (+5.18%)
NVDA   514.70 (+4.21%)
BABA   270.64 (+0.34%)
CGC   14.13 (-0.98%)
GE   6.11 (+0.83%)
MU   49.10 (-0.75%)
AMD   78.05 (+2.94%)
T   28.03 (-0.04%)
F   6.52 (-2.10%)
ACB   5.03 (-3.27%)
GILD   62.23 (-0.03%)
NFLX   481.88 (+1.86%)
DIS   124.00 (+1.23%)
BAC   23.49 (+0.64%)
BA   156.49 (+7.15%)
S&P 500   3,298.46 (+1.60%)
DOW   27,173.96 (+1.34%)
QQQ   271.75 (+2.40%)
AAPL   112.48 (+3.94%)
MSFT   207.74 (+2.24%)
FB   255.04 (+2.21%)
GOOGL   1,441.99 (+1.34%)
AMZN   3,094.00 (+2.46%)
TSLA   407.87 (+5.18%)
NVDA   514.70 (+4.21%)
BABA   270.64 (+0.34%)
CGC   14.13 (-0.98%)
GE   6.11 (+0.83%)
MU   49.10 (-0.75%)
AMD   78.05 (+2.94%)
T   28.03 (-0.04%)
F   6.52 (-2.10%)
ACB   5.03 (-3.27%)
GILD   62.23 (-0.03%)
NFLX   481.88 (+1.86%)
DIS   124.00 (+1.23%)
BAC   23.49 (+0.64%)
BA   156.49 (+7.15%)
Log in
NYSE:TEVA

Teva Pharmaceutical Industries Stock Forecast, Price & News

$8.73
+0.16 (+1.87 %)
(As of 09/25/2020 03:59 PM ET)
Add
Compare
Today's Range
$8.58
Now: $8.73
$8.76
50-Day Range
$8.64
MA: $10.01
$12.66
52-Week Range
$6.25
Now: $8.73
$13.76
Volume229,418 shs
Average Volume14.62 million shs
Market Capitalization$9.53 billion
P/E Ratio3.78
Dividend YieldN/A
Beta1.5
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides specialty medicines for use in central nervous system and respiratory indications. Its products in the central nervous system area comprise Copaxone for the treatment of relapsing forms of MS; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. This segment's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. The company has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.
Read More
Teva Pharmaceutical Industries logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 3.8 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.29 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone972-3914-8171

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.89 billion
Cash Flow$3.86 per share
Book Value$13.79 per share

Profitability

Net Income$-998,000,000.00

Miscellaneous

Employees40,039
Outstanding Shares1,092,189,000
Market Cap$9.53 billion
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$8.73
+0.16 (+1.87 %)
(As of 09/25/2020 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TEVA News and Ratings via Email

Sign-up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Teva Pharmaceutical Industries (NYSE:TEVA) Frequently Asked Questions

How has Teva Pharmaceutical Industries' stock been impacted by COVID-19 (Coronavirus)?

Teva Pharmaceutical Industries' stock was trading at $9.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TEVA stock has decreased by 3.4% and is now trading at $8.70.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Teva Pharmaceutical Industries?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 3 sell ratings, 9 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Teva Pharmaceutical Industries
.

When is Teva Pharmaceutical Industries' next earnings date?

Teva Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Teva Pharmaceutical Industries
.

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) released its quarterly earnings results on Wednesday, August, 5th. The company reported $0.55 EPS for the quarter, beating analysts' consensus estimates of $0.53 by $0.02. The company earned $3.87 billion during the quarter, compared to analysts' expectations of $3.94 billion. Teva Pharmaceutical Industries had a return on equity of 17.88% and a net margin of 0.03%. The firm's revenue for the quarter was down 7.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.60 EPS.
View Teva Pharmaceutical Industries' earnings history
.

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries updated its FY20 earnings guidance on Wednesday, August, 5th. The company provided earnings per share guidance of $2.30 to $2.55 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.49. The company issued revenue guidance of $16.6 billion to $17 billion, compared to the consensus revenue estimate of $16.83 billion.

What price target have analysts set for TEVA?

18 brokerages have issued 12 month price targets for Teva Pharmaceutical Industries' stock. Their forecasts range from $8.00 to $16.00. On average, they expect Teva Pharmaceutical Industries' share price to reach $12.36 in the next twelve months. This suggests a possible upside of 42.0% from the stock's current price.
View analysts' price targets for Teva Pharmaceutical Industries
.

Has Teva Pharmaceutical Industries been receiving favorable news coverage?

Headlines about TEVA stock have been trending extremely negative on Friday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Teva Pharmaceutical Industries earned a daily sentiment score of -4.1 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future.
View the latest news about Teva Pharmaceutical Industries
.

Who are some of Teva Pharmaceutical Industries' key competitors?

What other stocks do shareholders of Teva Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Intel (INTC), Bank of America (BAC), Gilead Sciences (GILD), Cisco Systems (CSCO) and Johnson & Johnson (JNJ).

Who are Teva Pharmaceutical Industries' key executives?

Teva Pharmaceutical Industries' management team includes the following people:
  • Mr. Kåre Schultz, Pres, CEO & Director (Age 58)
  • Mr. Michael McClellan, Exec. VP & CFO (Age 48)
  • Mr. Mark Sabag, Exec. VP of Global HR (Age 48)
  • Dr. Carlo de Notaristefani, Exec. VP of Global Operations (Age 61)
  • Dr. Hafrun Fridriksdottir, Exec. VP of Global R&D (Age 57)

What is Teva Pharmaceutical Industries' stock symbol?

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Who are Teva Pharmaceutical Industries' major shareholders?

Teva Pharmaceutical Industries' stock is owned by many different retail and institutional investors. Top institutional shareholders include Menora Mivtachim Holdings LTD. (1.64%), Phoenix Holdings Ltd. (1.07%), FMR LLC (0.75%), Harel Insurance Investments & Financial Services Ltd. (0.70%), Swiss National Bank (0.40%) and Sumitomo Mitsui Trust Holdings Inc. (0.38%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell, Rosemary A Crane, Sol J Barer and Sven Dethlefs.
View institutional ownership trends for Teva Pharmaceutical Industries
.

Which institutional investors are selling Teva Pharmaceutical Industries stock?

TEVA stock was sold by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Two Sigma Advisers LP, Psagot Investment House Ltd., Alberta Investment Management Corp, State of Wisconsin Investment Board, Personal Resources Investment & Strategic Management Inc., Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management, and Cambridge Investment Research Advisors Inc.. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Mark Sabag, Michael James Mcclellan, Richard Daniell, and Rosemary A Crane.
View insider buying and selling activity for Teva Pharmaceutical Industries
.

Which institutional investors are buying Teva Pharmaceutical Industries stock?

TEVA stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Orbimed Advisors LLC, Menora Mivtachim Holdings LTD., Teacher Retirement System of Texas, Harel Insurance Investments & Financial Services Ltd., Nuveen Asset Management LLC, ArrowMark Colorado Holdings LLC, and Schonfeld Strategic Advisors LLC.
View insider buying and selling activity for Teva Pharmaceutical Industries
.

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Teva Pharmaceutical Industries' stock price today?

One share of TEVA stock can currently be purchased for approximately $8.70.

How big of a company is Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries has a market capitalization of $9.50 billion and generates $16.89 billion in revenue each year. The company earns $-998,000,000.00 in net income (profit) each year or $2.31 on an earnings per share basis. Teva Pharmaceutical Industries employs 40,039 workers across the globe.

What is Teva Pharmaceutical Industries' official website?

The official website for Teva Pharmaceutical Industries is www.tevapharm.com.

How can I contact Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3914-8171 or via email at [email protected]

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.